NASDAQ: MNKD · Life Sciences · 2 alerts · CIK 899460
Share price
$3.95Close, Nov 16
Market cap
$1.27B
Shares outstanding
321.64MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834
Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Mannkind Corp filings on SEC EDGAR ↗
MannKind Corp reported total revenues of $101.9 million for the third quarter of 2026, a 24% increase year-over-year, driven by commercial product sales and royalties. However, the company swung to a net loss of $23.2 million for the quarter compared to a net income of $8.0 million in the prior year, primarily due to a significant increase in selling, general, and administrative expenses.
MannKind Corporation reported third quarter 2026 total revenues of $101.9 million, a 24% increase year-over-year, driven by the commercial launch of Furoscix ReadyFlow and strong pediatric uptake for Afrezza. The company also highlighted positive Phase 1b results for its nintedanib DPI program and a new licensing collaboration with Rose Pharma for an inhaled GLP-1.
“The third quarter marked an important transition for MannKind as we shifted from delivering on three major catalysts to executing against them. We are focused on scaling two commercial launches while supporting three programs in IPF. Furoscix ReadyFlow is off to an exceptionally strong start, and we believe Furoscix will generate more revenue in the fourth quarter than it did in the first half of 2026. ReadyFlow significantly expands the opportunity ahead and reinforces our conviction that Furoscix can be transformational for MannKind and the patients we serve.”
Michael Castagna, Chief Executive Officer of MannKind